Cozad Asset Management Inc. Has $14.37 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Cozad Asset Management Inc. boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 60.1% during the second quarter, Holdings Channel.com reports. The institutional investor owned 15,873 shares of the company’s stock after acquiring an additional 5,960 shares during the quarter. Eli Lilly and Company accounts for approximately 1.4% of Cozad Asset Management Inc.’s portfolio, making the stock its 14th largest position. Cozad Asset Management Inc.’s holdings in Eli Lilly and Company were worth $14,371,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Lynx Investment Advisory acquired a new position in Eli Lilly and Company during the second quarter worth approximately $32,000. Morton Brown Family Wealth LLC grew its position in shares of Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after purchasing an additional 15 shares during the last quarter. Core Wealth Advisors Inc. grew its position in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the last quarter. Activest Wealth Management acquired a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $39,000. Finally, Tidemark LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 876,900 shares of company stock worth $788,605,032 over the last three months. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on LLY shares. Wells Fargo & Company upped their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, August 19th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Finally, JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Stock Down 0.4 %

NYSE LLY opened at $956.53 on Wednesday. The business has a fifty day moving average price of $895.06 and a two-hundred day moving average price of $825.20. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The stock has a market capitalization of $909.09 billion, a PE ratio of 140.87, a PEG ratio of 2.91 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Equities analysts expect that Eli Lilly and Company will post 16.51 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.54%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is presently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.